NP not selling the company - Will have tons of revenue, can hire any expertise we (oops, they) will need, can outsource in the interim. Worst case can partner with big pharma on individual indications but way too many shots on goal to give everything away at an affordable price.

This isn’t a typica 2-4 indication, 2-4 drug pipeline small co or some unique technological platform like a NGIO or something that big pharma can easily tuck in.

If HIV and Covid hits and our (oops, their) cancer trials show any continued success in human trials, this is no longer a tuck in co. Merger at most...